Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 6Phase 1/2 5Phase 1 4Phase 2/3 1

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 5INDUSTRY 4NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4

Conditions

Glioblastoma 3Neoplasms 1Glioma 1Brain Neoplasms 1

Interventions

pembrolizumab 301Paclitaxel 206Carboplatin 199Gemcitabine 173Cisplatin 138Docetaxel 137Cyclophosphamide 135Nivolumab 129Bevacizumab 118Injections 111fludarabine 95atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 70Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Lomustine × Clear all
NCT01682187 2024-11-07

A Dose-Escalation Study in Participants With Recurrent Malignant Glioma

Eli Lilly and Company

Phase 1 Completed
66 enrolled
CNS

Glioma

NCT05304663 2024-04-08

GLIOASTRA

Philogen S.p.A.

Phase 1 Withdrawn
CNS

Glioblastoma

NCT01934361 2020-12-09

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

Novartis

Phase 1 Completed
35 enrolled
CNS

Glioblastoma

NCT00503204 2009-11-25

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

AstraZeneca

Phase 1 Completed
20 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡